Assessing prognoses and validating surrogate end points for clinical outcomes in metastatic hormone-sensitive prostate cancer

Duke University's Office of Research Administration received a $1.54M project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award funds research activities focused on assessing prognoses and validating surrogate endpoints for clinical outcomes in metastatic hormone-sensitive prostate cancer. This research initiative aligns with the Defense Health Agency's mission to support hypothesis-driven biomedical research that transforms healthcare for military service members and the American public through innovative medical solutions.

The grant supports translational and clinical research services delivered at Duke University's Durham, North Carolina facility, leveraging the institution's established expertise in oncology research and clinical trial infrastructure. As a leading academic medical center with demonstrated capacity to execute complex federal research programs, Duke will conduct investigative work designed to advance understanding of prostate cancer prognosis and identify validated clinical biomarkers to improve patient outcomes. The project is subject to the Military Medical Research and Development program's two-tier competitive review process, which emphasizes both technical merit and military relevance in advancing cancer research priorities.